MAGEC2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: 293T and Jurkat cell lysates, Primary antibody: P10129(MAGEC2 Antibody) at dilution 1/850, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P10129(MAGEC2 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P10129(MAGEC2 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The MAGEC2 (Melanoma Antigen Gene Family C2) protein, a member of the MAGE cancer-testis antigen (CTA) family, is predominantly expressed in germline cells and placental tissues under normal physiological conditions. However, it is aberrantly overexpressed in various malignancies, including melanoma, hepatocellular carcinoma, lung cancer, and multiple myeloma. This tumor-restricted expression pattern makes MAGEC2 a promising target for cancer immunotherapy and biomarker research.

MAGEC2 antibodies are immunological tools designed to detect and study the expression, localization, and functional roles of MAGEC2 in both normal and pathological contexts. These antibodies are widely utilized in techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to investigate MAGEC2's association with tumor progression, metastasis, and immune evasion. Studies suggest MAGEC2 contributes to oncogenesis by regulating epigenetic modifiers (e.g., histone deacetylases) and promoting cell proliferation.

Clinically, MAGEC2 antibodies hold dual significance: as diagnostic aids to identify MAGEC2-positive tumors and as potential therapeutic enablers for targeted immunotherapies, such as CAR-T cells or vaccine-based approaches. However, challenges persist due to MAGEC2's high homology with other MAGE family proteins, raising risks of cross-reactivity in antibody-based applications. Additionally, its role in immune tolerance mechanisms necessitates rigorous validation to ensure specificity and safety in therapeutic contexts. Research continues to optimize MAGEC2-targeting strategies for precision oncology applications.